What is the appropriate evaluation and management for a patient with elevated liver enzymes?

Evaluation and Management of Elevated Liver Enzymes

Begin by determining the pattern of enzyme elevation—hepatocellular (ALT/AST predominant) versus cholestatic (alkaline phosphatase/bilirubin predominant)—as this immediately narrows your differential diagnosis and directs subsequent testing. 1

Initial Clinical Assessment

Obtain specific details about:

• Alcohol consumption using AUDIT-C screening, with full 10-item AUDIT if positive (>19 indicates dependency requiring referral to alcohol services) 1
• Metabolic risk factors: BMI >25, type 2 diabetes, dyslipidemia, hypertension—all suggesting NAFLD 1
• All medications including vitamins, herbs, and over-the-counter drugs that may cause drug-induced liver injury 1
• Risk factors for viral hepatitis: injection drug use, transfusions, sexual exposures 2

Pattern-Based Diagnostic Approach

Hepatocellular Pattern (ALT/AST Elevation)

For mild elevations (<5× upper limit of normal):

First-line serologic testing should include 1, 2:

• Hepatitis B surface antigen and hepatitis B core antibody-IgM
• Hepatitis C antibody (consider HCV-RNA if positive)
• Complete blood count with platelets
• Serum albumin and prothrombin time
• Iron studies (serum iron, total iron-binding capacity, ferritin) for hereditary hemochromatosis
• Fasting lipid panel and glucose/HbA1c for metabolic syndrome
• TSH for thyroid disorders

The two most common causes are nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease, accounting for the majority of cases in primary care. 2

Risk Stratification for NAFLD

All adults with NAFLD must undergo fibrosis risk stratification using validated non-invasive tests 1:

First-line: Calculate FIB-4 or NAFLD Fibrosis Score 1

• These should be incorporated into primary care computer systems for automatic calculation

Second-line: If first-line tests suggest intermediate or high risk, obtain 1:

• Enhanced Liver Fibrosis (ELF) score, OR
• Fibroscan/ARFI elastography

Alcohol-Related Liver Disease Assessment

For patients drinking ≥50 units/week (men) or ≥35 units/week (women): 1

• Perform Fibroscan/ARFI elastography to detect cirrhosis and advanced fibrosis
• Refer to secondary care if Fibroscan >16 kPa or evidence of cirrhosis/portal hypertension 1

Critical synergy: When BMI >35, the risk of liver disease doubles for any given alcohol intake 1

Cholestatic Pattern (Alkaline Phosphatase/Bilirubin Elevation)

Determine if hyperbilirubinemia is conjugated (direct) or unconjugated (indirect) 1:

• Isolated unconjugated hyperbilirubinemia in asymptomatic adults: evaluate for Gilbert's syndrome, hemolysis, medication-induced causes 1
• Conjugated hyperbilirubinemia: assess for biliary obstruction with imaging; exclude primary biliary cholangitis and primary sclerosing cholangitis with appropriate antibodies 1

When to Refer to Hepatology

Immediate referral is warranted for 1:

• Markedly elevated transaminases (>5× upper limit of normal) 3
• Evidence of hepatic decompensation (abnormal albumin, prolonged prothrombin time, ascites, encephalopathy)
• Chronic elevation persisting ≥6 months despite negative initial workup 1
• Negative extended liver etiology screen with no NAFLD risk factors—treatable conditions like autoimmune hepatitis may have normal autoantibodies and immunoglobulins 1
• Fibroscan >16 kPa in alcohol-related disease 1

Common Pitfalls to Avoid

Do not assume normal liver tests exclude advanced disease: Normal enzymes do not rule out cirrhosis, particularly in alcohol-related disease 1

Do not overlook autoimmune hepatitis: Some cases present with no detectable autoantibodies or normal immunoglobulins, making them easily missed 1

Do not ignore the obesity-alcohol synergy: Patients with elevated BMI and moderate alcohol intake face exponentially higher risk than either factor alone 1

Do not delay evaluation in chronic elevation: Persistently abnormal enzymes for ≥6 months typically warrant liver biopsy consideration after non-invasive testing 1

Management of Common Causes

For NAFLD with confirmed fibrosis (F2-F3): Lifestyle modification remains cornerstone therapy; semaglutide 2.4 mg/week subcutaneously is FDA-approved for MASH with moderate-to-advanced fibrosis based on ESSENCE trial data showing 62.9% MASH resolution versus 34.3% placebo 4

For alcohol-related disease with AUDIT >19: Mandatory referral to alcohol dependency services alongside hepatology 1

Treatment response monitoring in NAFLD: Expect ALT reduction >17 U/L or ≥20%, and imaging parameter improvements (CAP ≥30%, Fibroscan LSM ≥30%) by 72 weeks 4